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By DAVID M. CUTLER AND MARK MCCLELLAN*
Research on productivity change in health
care has surged in recent years. This interest
reflects both policy interest in the value of
health care and improving data capabilities and
methods for productivity research. Because of
the central importance of quality change in
health care, this research has directly or indi-
rectly considered not only changes in the costs
of producing health services (e.g., the cost of a
hospital day), but also changes in the benefits of
health services for patient health.
Some studies have compared overall changes
in population health to changes in aggregate
medical expenditures. For example, recent stud-
ies by Kevin Murphy and Robert Topel (1999)
and William Nordhaus (1999) suggest that the
value to current and future generations of Amer-
icans of improvements in life expectancy in
recent decades has exceeded $2 trillion per year.
Accounting for the improvements in age-
adjusted functional health that also appear to
have occurred in recent decades (e.g., Kenneth
Manton et al., 1997) makes the improvement
in health even greater. Cutler and Elizabeth
Richardson (1999) estimate that, even if only 25
percent of the overall improvement in health is
attributable to medical care, then health-care
productivity has risen.
Yet translating this into health-care produc-
tivity calculations leaves many issues unre-
solved. It is not immediately clear how to
determine the share of health improvements that
result from medical care. Further, even if over-
a,ll productivity improvements have been high,
it is possible that many changes in health-care
productivity have been less valuable. Identify-
ing areas of high and low past and potential
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future productivity improvements would be
helpful for guiding policymakers.
For all of these reasons, much of the recent
research on health-care productivity has fo-
cused on explicit analysis of costs and outcomes
for certain common, serious health problems,
where other factors can be controlled for and
relevant inputs and health outcomes can be
measured. In this paper, we review the "state of
the art" of the evidence on health-care produc-
tivity. We first summarize a set of recent pro-
ductivity studies of common conditions that
account for a substantial fraction of overall
medical spending. These studies also illustrate
the range of methods that have been used in
disease-level productivity studies. In general,
the studies show rather substantial productivity
gains in care. We then present new evidence on
productivity of treatment for breast cancer, a
disease that, at least in its most common forms
in adults, many experts believe has seen little
improvement in benefits of care over time. Con-
sidering cancer allows us to focus on a condi-
tion where there is no presumption that medical
care has been worthwhile, and where there are a
host of complex issues related to case-finding,
the timing of diagnoses, and chronic care. We
find that the treatment of cancer has had at best
small productivity improvements. Outcomes
have improved more on a per-case basis than
when considering the population as a whole.
I. Previous Studies of Health-Care
Productivity Change
Previous studies have measured the produc-
tivity of medical care in one of two ways (see
Cutler and Ernst Bemdt [2001] for detailed dis-
cussion). One set of studies has explicitly mea-
sured changes in the costs of care and outcomes
of population cohorts with specific health prob-
lems over time. Cutler et al. (1998, 2001) used
longitudinal data on the treatments, hospital
costs of care, and health outcomes for the vast
majority of elderly Medicare beneficiaries hos-
pitalized with new heart attacks between 1984
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and 1994. They documented a significant im-
provement in long-term life expectancy of
roughly one year per heart-attack patient, due
primarily to improvements in acute mortality
that persisted for many years.
Valuing years of life is difficult. A common
estimate in the literature is that an additional
year of life is worth perhaps $100,000 (W. Kip
Viscusi, 1993). Adjusting for the lower quality
of life expected for people with these serious
conditions, we use a value of $75,000 per
year. This estimate is clearly subject to some
error; in general, we draw firm conclusions
only in situations where a very wide range of
values for a year of life give consistent an-
swers. With this assumption, the benefits of
medical-treatment changes for heart-attack
treatments exceed the costs by $87,000 per
person with a heart attack, representing a
substantial increase in productivity.
Similarly, Cutler and Ellen Meara (2000)
used repeat cross-sectional data on childbirth
expenditures and mortality from 1950-1990 to
quantify the changes in costs and outcomes for
childbirth explicitly. Between 1950 and 1990,
the average low-birth-weight infant lived an
additional 12 quality-adjusted years owing to
improvements in medical care in the postnatal
period (neonatal intensive-care units, ven-
tilators, etc.). The cost increase was nearly
$40,000, large but nowhere near as large as
the health gains. The net benefit of treatment
changes is nearly $200,000 per low-birth-
weight infant.
While direct studies of changes in outcomes
and costs of care are perhaps the most com-
pelling approach to evaluating productivity
change, studies like these have some limita-
tions. First, it is hard to control for all of the
improvements in health outcomes. For each of
these conditions, there is evidence that medical-
technology changes account for the bulk of the
health improvement. Paul Heidenreich and
McClellan (2001a, b) concluded that at most
20-30 percent of the improvement in heart-
attack mortality during this time period could be
attributed to nonmedical factors. Cutler and
Meara (2000) argue that, conditional on birth
weight, intensive technologies are virtually the
only reason for changes in outcomes over time.
But such arguments will not always be possible.
In addition, it is difficult to measure all of the
quahty factors that patients value. In the case of
heart attacks, we found no evidence of offset-
ting increases in forms of heart disease such as
angina and congestive heart failure that were
large enough to alter our conclusions substan-
tially, but we could not look at all possible
outcomes.
A second set of studies confronting these
problems has chosen a different method of pro-
ductivity assessment. In particular, they have
combined clinical data on the average effective-
ness of therapies with administrative data on
changes in utilization over time. For example,
Ernst Bemdt et al. (2000) have estimated the
value of recent changes in care for depression
by combining the results of clinical studies with
data on trends in treatment patterns. Bemdt et
al. show that, over the 1991-1996 period, there
was a large shift of patients away from psycho-
therapeutic approaches and toward pharmaco-
logical management of depression. The cost of
this technology change was minimal; pharma-
ceutical management is actually cheaper than
psychotherapy. But the change brought health
benefits. More people taking pharmaceuticals
received guideline levels of care than was the
case when psychotherapy predominated. Thus,
average spending per incremental remission of
depressive symptoms fell by nearly 20 percent
over this time period, effectively an increase in
productivity.
Similarly, Irving Shapiro et al. (2001) used a
detailed review of the clinical literature on both
costs and benefits of surgical treatment for cat-
aracts to evaluate changes in productivity of
care for cataracts. Over the past several decades,
a range of improvements in surgical techniques
and replacement lens devices have dramatically
reduced the cost, time, and morbidity associated
with cataract extraction procedures. Hospital
stays for the surgery have declined from over a
week in the early 195O's to only a few hours
today, and complications such as infections are
much less common. At the same time, improved
lenses and techniques have also led to higher-
quality vision after cataract excision. Shapiro et
al. estimate an index of the change in cost of the
procedure by multiplying the average use of
each major type of medical resource (hospital
day, operating room, surgeon) in producing the
operation at a given time by the medical price
index for that type of input (see Shapiro et al..VOL. 91 NO, 2 PRICE AND QUALITY MEASUREMENT 283
2001 p. 20). By using current prices for each
input, they account for the fact that these inputs
have generally become more intensive over
time. They conclude that the real cost of a
cataract excision declined over time by about
1.6 percentage points per year. Although they
do not provide an estimate of the change in
quality of care, the evidence from the clinical
literature of increasing quality strongly suggests
that productivity rose.
These indirect studies have their limita-
tions as well. Most importantly, the effects of
treatments are likely to be heterogeneous;
for example, certain drugs may be effective
for treating some depressed patients, while
other drugs or psychotherapy may be more
effective for others. Because these studies
do not directly measure outcome changes,
they do not account for potentially important
productivity effects in terms of how treat-
ments are allocated. Such allocation quality
could either improve over time (better in-
formation on who should get what care) or
decline (forced standardization resulting
from managed care). In addition, as the costs
and morbidity of treatment decline, patients
with milder forms of disease or earlier stages
of disease are likely to receive treatment,
which may reduce, or increase, treatment
efficacy.
Despite different approaches and different
limitations, the direct and indirect studies of
productivity changes in the treatment of com-
mon diseases universally show that produc-
tivity is rising, and by large amounts (see
Table 1). Still, while the conditions reviewed
here account for around one-sixth of medical
spending, it is possible that they are not rep-
resentative. In particular, chronic diseases
such as diabetes and congestive heart failure,
for which no "curative" procedures exist,
have been understudied. Further, the clinical
evidence suggests that health outcomes have
not improved much for some important con-
ditions, despite innovations in treatment. The
most obvious such disease is cancer. Despite
a variety of potentially costly innovations in
screening and treatment, population mortality
rates from breast cancer, an important out-
come measure for the condition, did not de-
cline through the 198O's and have fallen only
modestly in very recent years.
TABLE 1—ESTIMATES OF PRODUCTIVITY CHANGE
IN TREATMENT OF COMMON HEALTH PROBLEMS
Condition
Heart attack
Low-birth-
weight
itifatits
Depression
Cataracts
Years
1984-1994
1950-1990
199t..-1996
1969-1998
Cost
change
($)
7,000
39,000
-364
Outcome
Change
1 year"
12 years"
b
c
Value
($l,OOO's)
94
238
Net benefit
($l,OOO's)
87
199
>0
Notes: Value assumes that willingness to pay for a year in perfect health is
$100,000 or ahout $75,000 given quality-of-Iife disutility from these conditions.
Details of particular conditions can be found in Cutler et al. (2001) [heart
attacks]. Cutler and Meara (2000) [low-hirth-wcight infants], Bemdt et al.
(2000) [depression], and Shapiro et al. (2001) [cataracts]. Cost changes were
calculated by the authors from reported results.
" Increase in life expectancy.
** Cost per expected remission falls by 20 percent.
"^ No direct evidence reported; indirect evidence suggests substantial im-
provements in quality of procedure.
II. New Evidence on Productivity Change
in Breast-Cancer Care
To expand the range of what is known, we
consider the productivity of treatment changes
for breast cancer. We analyze cancer registry
data from the Surveillance, Epidemiology, and
End Results (SEER) program linked to compre-
hensive Medicare claims records for the vast
majority of elderly registry patients diagnosed
with new cases of breast cancer between 1984
and 1991. The SEER data provide accurate in-
formation on the nature and extent of cancer
(e.g., stage). The Medicare claims allowed us to
estimate longitudinal costs of treatment, analo-
gous to our previous work on heart attacks.
More details are available in our technical paper
(Cutler and McClellan, 2001).
As an approximation to the impact of cancer
treatment on lifetime medical costs, we calcu-
lated the discounted difference in total Medicare
expenditures in the eight years after diagnosis
(including all types of inpatient, ambulatory,
and physician services) for patients with breast
cancer versus age-matched beneficiaries with-
out breast cancer. Costs for years beyond our
follow-up period (through 1998) were imputed
based on the relative spending differences ob-
served for earlier cohorts. The data were linked
to complete death index records, including in-
formation on whether breast cancer was the
underlying cause. We constructed estimates of
changes in life expectancy by assuming that the284 AEA PAPERS AND PROCEEDINGS MAY 2001
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FIGURE 1. INCIDENCE OF DIAGNOSED BREAST CANCER
IN THE ELDERLY
Source: Authors' analysis of SEER-Medicare linked data.
same relative differences in survival observed
for patients with and without breast cancer dur-
ing our followup period (through 1998) would
continue. Thus, our estimates are based on ac-
tual patient follow-up for at least seven years
after diagnosis.
With more emphasis on breast-cancer screen-
ing through greater use of mammography and
other procedures, there was a shift toward earlier
diagnosis of breast cancer over time (Fig. 1). This
trend included a shift in the timing of diagnosis,
from later advanced (metastatic) cases to earlier
detection of milder cases.' In addition, there was
an increase in the overall rate of cancer detection:
the increase in the incidence of local-stage cancer
detection more than exceeds the decline over time
in metastatic cancer detection. This may reflect
two phenomena: either the true incidence of can-
cer has increased (e.g., because of increases in risk
factors such as fewer or later pregnancies and
higher income), or more cancers are being de-
tected that previously were not detected and
treated (e.g., because the patient died of other
causes before the cancer had progressed to a
symptomatic stage). Differentiating between these
two hypotheses is important. If the change in
' Other things equal, increased detection will create a
temporary increase in the incidence of new cases of an
illness, as more cases are identified that would have been
detected later, possibly at a more severe stage. In the long
run, the overall case incidence will return to its equilibrium
level, with a higher share of early^stage cases and a lower
share of late-stage cases.
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FIGURE 2. BREAST-CANCER MORTALITY TRENDS
Source: National Center for Health Statistics.
overall detection is exogenous to medical care, we
would not want to count the increased population
mortality rate implied by the change as a negative
productivity change. But if the change in detection
is a result of screening changes, we want to in-
clude the costs and benefits of this increased de-
tection change in our productivity calculations. In
particular, if more intensive case-finding did not
lead to improvements in cancer outcomes, then
the per capita costs of cancer care in the popula-
tion would rise, but population outcomes from
cancer would not improve.
Figure 2, which shows trends in demograph-
ically adjusted population mortality rates, sug-
gests that increased case-finding may have had
some impact on population outcomes. After in-
creasing slightly over the previous two decades,
population mortality rates began to decline
gradually in 1991. However, because popula-
tion mortality reflects cancer incidence and out-
comes in many preceding cohorts, it is a
dampened and delayed measure of the long-
term outcome consequences of improvements
in cancer care from year to year.
We developed methods for analyzing cohorts
of new cancer patients that account explicitly
for the changes in treatment rates in the popu-
lation from year to year. Our case method for
analyzing productivity change is analogous to
the approach taken in the previous literature of
comparing changes in costs and important out-
comes for the average patient treated over time.
This method assumes that the observed changes
in incidence are real (i.e., the underlying cancer
rate in the population has risen). Thus, to mea-
sure productivity change, we simply compare
costs and benefits for diagnosed patients in dif-
ferent years. In contrast, our population method
compares changes in the costs and outcomes of
breast cancer for the average woman in theVOL. 91 NO. 2 PRICE AND QUAUTY MEASUREMENT 285
TABLE 2—COSTS AND BENEFITS OF CHANGES
IN TREATMENT FOR BREAST CANCER
Year
1985
1991
Change:
Case
Average
cost
$14,809
$20,160
$5,351
method
Life
expectancy
8 yr 5 mo
9 yr 1 mo
8 mo
($34,886)
Population method
Average
cost
$16,553
$25,425
$8,872
Life
expectancy
NA"
NA"
2 mo"
($10,997)
Note: Costs are relative to the Medicare population as a
whole. The discounted value of life expectancy assumes that
a year is worth $75,000.
"NA = not available. Population life expectancy change
attributable to changes in breast cancer outcome is calcu-
lated from the increase in population life expectancy cor-
rected for the increase in breast cancer incidence.
population. This method assumes that the ob-
served changes in incidence are a result of
increased detection of "subclinical" cases.
Thus, increased detection and more intensive
treatment are beneficial only to the extent that
they actually improve outcomes for the popula-
tion as a whole. If early detection is on net
beneficial, the gains could be even greater than
with the case method. But if early detection
reflects increased diagnosis and treatment of
cases that would not have developed into life-
threatening cases, the change might reduce pro-
ductivity.^
Table 2 summarizes the results. Average
spending per case increased substantially, by
over $5,000 (in 1991 dollars). This increase in
expenditures was accompanied by an increase
in life expectancy of eight months. Thus, with
reasonable valuations of life (e.g., $75,000
for a year in good health), the increases in
costs have been well worth it, though the
gains have been less impressive than for
the other conditions reviewed in Table 1. In
contrast, the population method suggests that
the higher costs of treatment have been
roughly commensurate to the value of the
life-expectancy gains. A small gain in overall
survival has occurred, but the net benefit de-
^ Neither method accounts for the out-of-equilibrium
phenomenon discussed in footnote 1; thus, these methods
are best applied before and after a change in disease screen-
ing occurs.
pends importantly on the value of a year of
life. No strong conclusion about population-
level health changes can be drawn from these
results, though there is no evidence that pro-
ductivity declined substantially.
III. Conclusion
Though they are not without limitations, re-
cent disease-based studies are providing a new
type of evidence on rising productivity in health
care. In the case of cataracts and depression,
productivity growth appears to have occurred as
a result of a decline in per-case treatment costs.
In these diseases, total treatment expenditures
may well have risen, because of an associated
rise in treatment rates as treatment improves. In
the case of other serious illnesses, treatment
intensity (both in terms of screening procedures
and therapies) has risen, leading to increasing
per-case expenditures, but also to improvements
in outcomes that make the rising intensity
worthwhile. Our new results on breast cancer
suggest that, even for an illness that has been
widely regarded as showing little improvement
despite rising costs, productivity has not
declined.
Further research should help expand and
clarify the emerging picture of health-care
productivity growth. First, it is possible that
productivity trends in more recent years have
been different, as a result of newer innova-
tions and changes in health-care markets. Sec-
ond, chronic illnesses, such as diabetes or
heart failure, and illnesses associated with
significant disabilities that often involve long-
term supportive care, such as hip fracture or
stroke, are increasingly important compo-
nents of health care. Studies of chronic ill-
nesses will require extensions of the cohort
methods used in previous research and more
attention to changes in quality of life and their
valuation. Third, as a broader range of disease
studies becomes available, it should become
easier to develop an integrated, patient-level
perspective in evaluating health-care produc-
tivity. Finally, the emerging methods for eval-
uating productivity change can be applied in
clinical evaluations of new medical treatments,
as well as in evaluating the consequences of
economic and policy influences on the health-
care system.286 AEA PAPERS AND PROCEEDINGS MAY 2001
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